Efficacy and safety of pemafibrate versus bezafibrate in coronary artery disease patients receiving statin treatment: a randomized, open-label, cross-over study

Back

ESC Professional Premium Access

Efficacy and safety of pemafibrate versus bezafibrate in coronary artery disease patients receiving statin treatment: a randomized, open-label, cross-over study

Session: Current issues in lipid-lowering therapy

Topic: Lipid-Lowering Agents

Speaker: Doctor A. Nakamura (Morioka, JP)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Akihiro Nakamura

Iwate Prefectural Central Hospital, Morioka (Japan)

0 follower

5 more presentations in this session

LDL levels and long-term all-cause mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies.

Speaker: Professor M. Banach (Lodz, PL)

Access

Abstract

Slides

Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain

Speaker: Professor V. Barrios (Madrid, ES)

Access

Abstract

Slides

Statin therapy in children with familial hypercholesterolemia: A meta-analysis.

Speaker: Doctor J. Lewek (Lodz, PL)

Access

Abstract

Slides

Low-density lipoprotein cholesterol target attainment among statin-naive Chinese atherosclerotic vascular disease patients

Speaker: Ms H. Sun (Shatin, HK)

Access

Abstract

Slides

High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry

Speaker: Doctor M. Sibartie (Uxbridge, GB)

Access

Abstract

Slides

Access the full session

Current issues in lipid-lowering therapy

Speakers: Doctor A. Nakamura, Professor M. Banach, Professor V. Barrios, Doctor J. Lewek, Ms H. Sun...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources